Reni J. Benjamin
Stock Analyst at Citizens
(3.30)
# 1,063
Out of 5,116 analysts
13
Total ratings
36.36%
Success rate
11.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni J. Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Initiates: Market Outperform | $32 | $26.86 | +19.14% | 1 | Dec 3, 2025 | |
| ONC BeOne Medicines AG | Maintains: Market Outperform | $348 → $396 | $311.73 | +27.03% | 1 | Nov 7, 2025 | |
| SANA Sana Biotechnology | Maintains: Market Outperform | $5 → $8 | $4.53 | +76.60% | 1 | Oct 30, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Market Outperform | $40 | $18.38 | +117.63% | 3 | Oct 20, 2025 | |
| KURA Kura Oncology | Reiterates: Market Outperform | $24 | $11.06 | +117.00% | 2 | Oct 20, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $80.36 | - | 1 | Aug 22, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $4 → $3 | $0.66 | +354.27% | 1 | Aug 21, 2025 | |
| PRLD Prelude Therapeutics | Maintains: Market Outperform | $4 → $3 | $2.24 | +33.93% | 1 | Aug 18, 2025 | |
| BCAB BioAtla | Downgrades: Market Perform | n/a | $0.72 | - | 1 | Aug 13, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $22 → $10 | $6.99 | +43.06% | 1 | Aug 12, 2025 |
Zymeworks
Dec 3, 2025
Initiates: Market Outperform
Price Target: $32
Current: $26.86
Upside: +19.14%
BeOne Medicines AG
Nov 7, 2025
Maintains: Market Outperform
Price Target: $348 → $396
Current: $311.73
Upside: +27.03%
Sana Biotechnology
Oct 30, 2025
Maintains: Market Outperform
Price Target: $5 → $8
Current: $4.53
Upside: +76.60%
Summit Therapeutics
Oct 20, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $18.38
Upside: +117.63%
Kura Oncology
Oct 20, 2025
Reiterates: Market Outperform
Price Target: $24
Current: $11.06
Upside: +117.00%
Inhibrx Biosciences
Aug 22, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $80.36
Upside: -
Werewolf Therapeutics
Aug 21, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $0.66
Upside: +354.27%
Prelude Therapeutics
Aug 18, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $2.24
Upside: +33.93%
BioAtla
Aug 13, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.72
Upside: -
Bicycle Therapeutics
Aug 12, 2025
Maintains: Market Outperform
Price Target: $22 → $10
Current: $6.99
Upside: +43.06%